Press Release
19 April 2021
Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May
Immunicum AB (publ) today announced that it will participate and deliver multiple presentations featuring its proprietary Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP-001, at the following upcoming scientific conferences:
- Neoantigen Summit Europe, April 20 - 22, 2021
- Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, will make an oral presentation on "Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines", on Wednesday, April 21st at 2:45 pm CET / 8:45 am ET.
- Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, will make an oral presentation on "Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines", on Wednesday, April 21st at 2:45 pm CET / 8:45 am ET.
- Cancer Immunotherapy (CIMT) Annual Meeting, May 10 - 12, 2021.
- Alex Karlsson-Parra will deliver an oral presentation on "Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a "tumor-matched" phenotype" (S1-15), in eTalk Session 1 on Monday, May 10 from 2:00 - 3:00 pm CET / 8:00 - 9:00 am EDT.
- Satwinder Kaur Singh, Director of Research at Immunicum, will have an oral presentation titled "CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001" (S2-132), in eTalk Session 2 on Tuesday, May 11 from 5:00 - 6:00 pm CET/ 11:00 am - 12:00 pm EDT.
- Accepted abstracts for the CIMT Annual Meeting will be published on Monday May 3rd and will also be available in the online program book at the conference website www.meeting. (http://www.meeting.cimt.eu)cimt.eu (http://www.meeting.cimt.eu).
- Alex Karlsson-Parra will deliver an oral presentation on "Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a "tumor-matched" phenotype" (S1-15), in eTalk Session 1 on Monday, May 10 from 2:00 - 3:00 pm CET / 8:00 - 9:00 am EDT.
For more information, please contact:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: info@immunicum.com
Investor Relations
Sijme Zeilemaker
Head of Investor Relations & Corporate Communication
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
Media Relations
Eva Mulder and Sophia Hergenhan
Trophic Communications
Telephone: +49 175 222 57 56
E-mail: immu@trophic.eu
About Immunicum AB (publ)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
- 20210419_Immunicum_Upcoming_Industry_Meetings_FINAL_ENG (https://ml-eu.globenewswire.com/Resource/Download/b9359657-b9f5-4906-8a52-7eb9dc8b8f5b)
